Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3/NF-B feedback loop

BackgroundMulti-drug resistance (MDR) is one of the main obstacles for treatment of advanced/recurrent hepatocellular carcinoma (HCC). We have previously identified arsenic trioxide (ATO) as an effective metastasis/angiogenesis inhibitor in HCC. Here, we further found that MDR-HCC cells were more sensitive to ATO.MethodsThe MDR-HCC cells were used as experimental models. Biological functions were investigated using cell transfection, polymerase chain reaction, western blot, southwestern blot, immunostaining, immunoprecipitation plus atomic fluorescence spectrometry, and so on.ResultsThe MDR-HCC cells underwent high oxidative stress condition, and employed adaptive mechanisms for them to survive; while ATO abolished such mechanisms via targeting the 14-3-3/nuclear factor kappa B (NF-B) feedback Loop. Briefly, in MDR cells, the increase of ROS activated NF-B signaling, which transcriptionally activated 14-3-3. Meanwhile, the activation of NF-B can be constitutively maintained by 14-3-3. As a NF-B inhibitor, ATO transcriptionally inhibited the 14-3-3 mRNA level. Meanwhile, ATO was also validated to directly bind to 14-3-3, enhancing the degradation of 14-3-3 protein in an ubiquitination-dependent manner. Knockdown of 14-3-3 reduced the ATO-induced reversal extents of drug resistance in MDR cells.Conclusion14-3-3/NF-B feedback loop plays an important role in maintaining the MDR phenotype in HCC. Moreover, via targeting such feedback loop, ATO could be considered as a potential molecular targeted agent for the treatment of HCC.